MGNX MacroGenics, Inc.
Healthcare$4.47-1.32%ClosedMarket Cap: $284.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
13.56
P/S
1.83
EV/EBITDA
-4.56
DCF Value
$-65.52
FCF Yield
-24.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.9%
Operating Margin
-40.5%
Net Margin
-44.8%
ROE
-147.8%
ROA
-32.3%
ROIC
-49.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.8M | 46.0% | $-33.4M | $-36.8M | $— | — |
| Q4 null | $41.2M | 71.3% | $-12.1M | $-14.2M | $— | — |
| FY null | $149.5M | 71.1% | $-72.8M | $-74.6M | $— | — |
| Q3 null | $72.8M | 81.6% | $18.6M | $16.8M | $— | — |
| Q2 null | $22.2M | 51.4% | $-36.8M | $-36.3M | $— | — |
| Q1 null | $13.2M | 45.6% | $-42.6M | $-41.0M | $— | — |
| Q4 null | $17.7M | 69.0% | $-52.8M | $-15.4M | $— | — |
| FY null | $148.3M | 91.7% | $-110.6M | $-67.0M | $— | — |
| Q3 null | $110.7M | 61.7% | $54.2M | $56.3M | $— | — |
| Q2 null | $10.8M | 73.9% | $-58.2M | $-55.7M | $— | — |
| Q1 null | $9.1M | 76.8% | $-53.8M | $-52.2M | $— | — |
| Q4 2023 | $10.7M | -343.2% | $-49.4M | $-46.1M | $-0.74 | — |